Table 1.

Unadjusted characteristics of patients initiating TKIs for CML or immunomodulatory drugs for multiple myeloma by plan funding status and time before and after parity*

Characteristics	CML cohort				Multiple myeloma cohort
	Preparity		Postparity		Preparity		Postparity
	Fully insured	Self-funded	Fully insured	Self-funded	Fully insured	Self-funded	Fully insured	Self-funded
	(n = 523)	(n = 638)	(n = 432)	(n = 489)	(n = 879)	(n = 961)	(n = 755)	(n = 731)
Patient characteristics
Age category, y, %
<45	40.3	38.6	36.3	35.4	8.8	8.1	7.3	8.8
45–54	31.4	28.8	30.6	33.7	29.9	30.6	31.0	27.6
55–64	28.3	32.6	33.1	30.9	61.3	61.3	61.7	63.6
Sex, % female	43.6	45.3	39.4	42.1	40.5	42.0	40.9	41.6
Census-level SES, %
Unemployed	5.6	5.6	5.5	5.6	5.6	5.7	5.3	5.2
Black population	12.6	14.6	13.2	11.9	14.5	16.6	12.8	11.4
Insured	86.7	86.5	85.9	86.7	86.3	86.6	87.3	87.6
Under FPL	12.4	13.0	13.2	12.2	13.2	12.8	11.9	11.4
Drug initiated
Brand imatinib	70.6	66.8	31.7	34.2	—	—	—	—
Generic imatinib	—	—	13.9	12.5	—	—	—	—
Dasatinib	16.4	16.9	29.9	33.1	—	—	—	—
Nilotinib	13.0	16.3	24.5	20.3	—	—	—	—
Lenalidomide	—	—	—	—	85.2	83.7	96.7	96.0
Thalidomide	—	—	—	—	14.8	16.3	3.3	4.0
Year treatment initiated
2008	17.4	16.9	—	—	17.5	18.7	—	—
2009	22.4	18.0	—	—	21.1	21.4	—	0.3
2010	15.9	16.8	0.2	0.8	15.1	17.4	0.9	1.1
2011	14.2	15.7	1.9	3.3	15.8	16.8	3.3	4.4
2012	9.8	13.8	13.0	10.0	12.2	11.4	10.9	9.0
2013	9.2	8.5	10.7	12.7	9.2	7.8	9.8	11.8
2014	9.6	7.5	13.0	10.6	7.2	5.6	10.9	10.8
2015	1.7	2.7	18.3	18.2	1.9	0.8	18.3	20.1
2016	—	0.2	25.0	20.9	—	—	26.4	26.4
2017	—	—	18.1	23.5	—	—	19.6	16.1
High-deductible health plan member
Yes	13.4	15.8	16.9	23.5	12.3	15.9	18.0	28.2
Quarter diagnosed
Q1	21.4	24.5	32.9	37.4	22.1	19.6	25.8	32.8
Q2	28.9	27.7	29.9	23.9	26.6	28.8	31.3	27.8
Q3	26.0	24.0	19.0	19.0	28.7	26.9	20.5	17.5
Q4	23.7	23.8	18.3	19.6	22.6	24.7	22.4	21.9

^*CML = chronic myeloid leukemia; FPL = federal poverty level; SES = socioeconomic status; TKI = tyrosine kinase inhibitor.